NEW YORK--(BUSINESS WIRE)--Orbsen Therapeutics Limited, a leading immunotherapy company focused on the development of cell therapies for diabetic and autoimmune diseases has announced that it is part of a consortium awarded a UKE7M grant from the UK Government’s Innovate UK program. Orbsen, headquartered in Galway, Ireland is the key provider of their advanced cell based immunotherapy – ORBCEL-C to be tested within the clinical network. The health consortium, jointly led by the National Institute for Health Research Birmingham Biomedical Research Center (NIHR BRC) and NHS Wales will ensure that more patients benefit from a new generation of therapies and enable UK Advanced Therapy Medicinal Product (ATMP) companies to reach the clinical market.
Orbsen CEO, Dr. Larry A. Couture said, “We are proud to join the Midland & Wales clinical network consortium and begin the process of making these powerful cell immunotherapies safe, routine and available across the UK.” Steve Elliman, Orbsen CSO, said, “We are delighted that the UK Government (Innovate UK) support the transformative potential of cell immunotherapies and understand that these advanced medicines will have the greatest impact on UK healthcare outcomes when they become routine medicines delivered at every NHS Trust in the UK.”
Founded in 2006 out of Ireland’s Regenerative Medicine Institute (REMEDI), Orbsen has since developed proprietary technologies focused on the isolation of pure and defined stromal cells. These cells hold great promise as an alternative to drugs and surgical procedures for a wide range of conditions including heart disease, arterial disease of the limbs, diabetes complications, arthritis and other inflammatory conditions. The treatment potential is linked to the cells’ natural capacity to dampen inflammation and promote healing, repair and regeneration of damaged tissues. Orbsen has patented a unique method for purifying these rare, therapeutic cells and currently has four approved clinical trials across the (EU) for patients suffering from Diabetic Foot Ulcers, Autoimmune Liver Disease, Diabetic Kidney Disease and Acute Respiratory Distress Syndrome.
Between 2013 and 2015, Orbsen has collaborated with some 30 independent research laboratories across the EU to secure more than €35 million in EU funding to accelerate the clinical development of cell therapy. For more information please visit www.orbsentherapeuticals.com